Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 3/20 | 0.53 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28614337 | 0.79 | KCNN4 (0.48) | KCNN4KCNA3TSHRDRD2DRD4 | |
| SCHEMBL1444134 | 0.77 | ATM (0.45) | KCNN4KCNA3TSHRDRD2DRD4 | |
| SCHEMBL2391883 | 0.75 | KCNN4 (0.46) | KCNN4TSHRDRD2DRD4OPRM1 | |
| SCHEMBL11496292 | 0.75 | CYP3A4 (0.36) | KCNN4TSHRDRD2DRD4OPRM1 | |
| SCHEMBL2390778 | 0.74 | KIF11 (0.44) | TSHROPRM1DRD3CYP19A1KCNH2 | |
| SCHEMBL1864749 | 0.74 | KCNN4 (0.57) | KCNN4KCNA3TSHRDRD2DRD4 | |
| SCHEMBL8157067 | 0.73 | KCNN4 (0.61) | KCNN4KCNA3TSHRDRD2DRD4 | |
| SCHEMBL13865449 | 0.72 | VCAM1 (0.48) | TSHRCYP3A4CYP2D6LMNAMEN1 | |
| SCHEMBL1605524 | 0.72 | KCNN4 (0.41) | KCNN4KCNA3TSHRDRD2DRD4 | |
| SCHEMBL31364199 | 0.71 | KCNN4 (0.59) | KCNN4KCNA3TSHRDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911308-A2 | METHODS OF TREATING TYROSINE KINASE INHIBITOR-INDUCED DIARRHEA | The Regents of the University of California (US) | 2021-11-24 | — | — | EP | claimed |
| WO-2020150517-A2 | METHODS OF TREATING TYROSINE KINASE INHIBITOR-INDUCED DIARRHEA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-07-23 | — | — | WO | claimed |
| US-20070293554-A1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-12-20 | — | — | US | claimed |
| EP-1248614-A4 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | UNIV CALIFORNIA (US) | 2005-05-04 | — | — | EP | claimed |
| US-6803375-B1 | IMMUNOMODULATION IN A MAMMALIAN PATIENT WITHOUT CAUSING SUBSTANTIAL INHIBITION OF CYTOCHROME P-450 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-10-12 | — | — | US | claimed |
| EP-1248614-A2 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | The Regents of The University of California (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001049663-A2 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-07-12 | — | — | WO | claimed |
| CN-117180260-A | Deoxyflavonoid-based T lymphocyte activity inhibition composition | 杭州卢特康生物科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-3911308-A2 | METHODS OF TREATING TYROSINE KINASE INHIBITOR-INDUCED DIARRHEA | The Regents of the University of California (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150517-A2 | METHODS OF TREATING TYROSINE KINASE INHIBITOR-INDUCED DIARRHEA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-07-23 | — | — | WO | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-6331564-B1 | TREATING DIARRHEA CAUSED BY INFLAMMATORY BOWEL DISEASE, AUTOIMMUNE DISEASES SUCH AS LUPUS, GLOMERULONEPHRITIS | ION PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| WO-2001049663-A2 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-07-12 | — | — | WO | disclosed |
| EP-0918514-A4 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | HARVARD COLLEGE (US) | 2001-05-09 | — | — | EP | disclosed |
| CN-1251037-A | Triarylmethane compounds for sickle cell disease | HARVARD COLLEGE (US) | 2000-04-19 | — | — | CN | disclosed |
| US-6028103-A | Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0918514-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1997034589-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293554-A1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | NFATC1, ORAI1, KCNMA1 | KCNN4 10/4885KCNA3 46/4885TSHR 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.